Rotavirus vaccine and health care utilization for diarrhea in U.S. children.

Background: Routine vaccination of U.S. infants with pentavalent rotavirus vaccine (RV5) began in 2006.

Influenza-like illness in a community surrounding a school-based outbreak of 2009 pandemic influenza A (H1N1) virus-Chicago, Illinois, 2009.

In April 2009, following the first school closure due to 2009 pandemic influenza A (H1N1) (pH1N1) in Chicago, Illinois, area hospitals were inundated with patients presenting with influenza-like illness (ILI). The extent of disease spread into the surrounding community was unclear. We performed a household survey to estimate the ILI attack rate among community residents and compared reported ILI with confirmed pH1N1 cases and ILI surveillance data (ie, hospital ILI visits, influenza testing, and school absenteeism).

Uptake, impact, and effectiveness of rotavirus vaccination in the United States: review of the first 3 years of postlicensure data.

Background: Rotavirus vaccine was recommended for routine use in US infants in 2006. Before the introduction of vaccine, rotavirus was the most common cause of severe gastroenteritis in children <5 years of age in the United States.

Methods: We reviewed published data to summarize the US experience during the first 3 years of its rotavirus vaccination program.

Sustained decline in rotavirus detections in the United States following the introduction of rotavirus vaccine in 2006.

Background: Following implementation of the rotavirus vaccination program in 2006, rotavirus activity in the United States declined dramatically in 2007-2008 but increased slightly in 2008-2009, despite greater vaccine uptake. To further evaluate impact of the vaccine program, we assessed trends in rotavirus testing and detection during 2009-2010.

Methods: We examined rotavirus testing data from July 2000 to June 2010 from the National Respiratory and Enteric Viruses Surveillance System to compare rotavirus season timing and peak activity in the pre- and postvaccine introduction eras.

Reduction of diarrhea-associated hospitalizations among children aged < 5 Years in Panama following the introduction of rotavirus vaccine.

Background: In March 2006, rotavirus vaccine (Rotarix, RV1) was introduced into the Panamanian national immunization program. We assessed the effect of vaccine on diarrhea-associated hospitalizations among young Panamanian children.

Methods: We obtained monthly numbers of diarrhea-associated hospitalizations among children aged ≤ 5 years during 2003 and 2008 from 5 health regions in Panama, representing 53% of the birth cohort.

Trends in healthcare utilization for diarrhea and rotavirus disease in privately insured US children <5 years of age, 2001-2006.

Background: To assess impact of the new US rotavirus immunization program initiated in 2006, robust baseline data on diarrhea and rotavirus disease burden are needed. While several studies have assessed burden in inpatient settings, few data are available for emergency department (ED) and outpatient settings.

Methods: We used the MarketScan databases, a large claims-based data repository, to analyze the health and economic burden of diarrhea-related healthcare encounters in children <5 years in inpatient, ED, and outpatient settings from 2001 to 2006.